New research sheds light on how ketamine affects the brain by targeting a specific NMDA receptor subtype, GluN1-2B-2D.

B-2D, a brain receptor targeted by ketamine. Using cryo-EM, they visualize how ketamine binds to the receptor, controlling ...

Ketamine has received a Hollywood makeover. It used to be known as a rave drug (street name special K) and cat anesthetic.

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

IntroductionMajor depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing ...

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced ...

AV-101’s active metabolite, 7-Cl-KYNA, is not an ion channel blocker, unlike classic channel-blocking NMDA receptor antagonists such as ketamine and amantadine, which the Company believes is the ...